MA54058A - Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale - Google Patents
Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginaleInfo
- Publication number
- MA54058A MA54058A MA054058A MA54058A MA54058A MA 54058 A MA54058 A MA 54058A MA 054058 A MA054058 A MA 054058A MA 54058 A MA54058 A MA 54058A MA 54058 A MA54058 A MA 54058A
- Authority
- MA
- Morocco
- Prior art keywords
- endometriosis
- compositions
- treatment
- methods
- internal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752100P | 2018-10-29 | 2018-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54058A true MA54058A (fr) | 2021-09-08 |
Family
ID=68461757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054058A MA54058A (fr) | 2018-10-29 | 2019-10-29 | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12280052B2 (fr) |
| EP (1) | EP3873465B1 (fr) |
| AU (1) | AU2019373349B2 (fr) |
| CA (1) | CA3117092A1 (fr) |
| MA (1) | MA54058A (fr) |
| WO (1) | WO2020089190A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| EP4719422A1 (fr) * | 2023-05-26 | 2026-04-08 | Pandora Endocrine Innovation B.V. | Unité posologique orale sans progestogène destinée à être utilisée dans la contraception féminine et le traitement de l'endométriose |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| PT1300398E (pt) | 2000-07-05 | 2006-07-31 | Astellas Pharma Inc | Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| EP1646389B1 (fr) | 2003-07-07 | 2008-09-10 | Neurocrine Biosciences, Inc. | Derives de pyrimidine-2, 4-dione utilises comme antagonistes du recepteur d'hormone liberant de la gonadotrophine |
| RU2418803C2 (ru) | 2005-10-19 | 2011-05-20 | Киссеи Фармасьютикал Ко., Лтд. | Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине |
| EP2535342B1 (fr) | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Sel de dérivé hétérocyclique condensé et cristal de celui-ci |
| JP6268093B2 (ja) | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| EP4223298A3 (fr) | 2013-03-15 | 2023-08-16 | AbbVie Inc. | Compositions pour le traitement des saignements menstruels lourds |
| WO2017040841A1 (fr) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Méthodes d'administration d'élagolix |
| BR112019002513A2 (pt) * | 2016-08-08 | 2019-05-14 | Kissei Pharmaceutical Co., Ltd. | uso e dosagem de agentes terapêuticos para endometriose |
| WO2018060501A2 (fr) * | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Méthodes de traitement des fibromes utérins et de l'endométriose |
| DK3634419T3 (da) | 2017-06-05 | 2025-03-31 | Kissei Pharmaceutical | Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| JP7459086B2 (ja) | 2018-11-07 | 2024-04-01 | キッセイ薬品工業株式会社 | エストロゲン依存性障害の治療のための組成物及び方法 |
-
2019
- 2019-10-29 MA MA054058A patent/MA54058A/fr unknown
- 2019-10-29 CA CA3117092A patent/CA3117092A1/fr active Pending
- 2019-10-29 EP EP19798018.8A patent/EP3873465B1/fr active Active
- 2019-10-29 WO PCT/EP2019/079448 patent/WO2020089190A2/fr not_active Ceased
- 2019-10-29 US US17/289,418 patent/US12280052B2/en active Active
- 2019-10-29 AU AU2019373349A patent/AU2019373349B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3117092A1 (fr) | 2020-05-07 |
| WO2020089190A2 (fr) | 2020-05-07 |
| AU2019373349B2 (en) | 2025-01-09 |
| EP3873465B1 (fr) | 2025-01-15 |
| EP3873465A2 (fr) | 2021-09-08 |
| AU2019373349A1 (en) | 2021-05-20 |
| US20220117969A1 (en) | 2022-04-21 |
| US12280052B2 (en) | 2025-04-22 |
| WO2020089190A3 (fr) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3612215A4 (fr) | Compositions et procédés pour le traitement d'inflammation pulmonaire | |
| MA49069A (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
| MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| EP3347469A4 (fr) | Méthodes et compositions pour le traitement du glaucome | |
| EP3402572A4 (fr) | Compositions et méthodes de traitement d'états inflammatoires allergiques | |
| EP3846830A4 (fr) | Méthodes et compositions pour le traitement de maladie musculo-squelettiques | |
| EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
| EP3651801A4 (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| EP3681498A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3512524A4 (fr) | Méthodes et compositions de traitement d'infections virales | |
| EP3866790A4 (fr) | Méthodes et compositions permettant le traitement du glaucome et d'affections apparentées | |
| EP3810091A4 (fr) | Méthodes et compositions pour le traitement de l'hypertension pulmonaire | |
| EP3454793A4 (fr) | Bobines de traitement d'anévrisme | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3641746A4 (fr) | Méthodes et compositions pour le traitement d'une infection microbienne | |
| EP3638293A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| EP3920898A4 (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| EP3688023A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3400008A4 (fr) | Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b | |
| EP3368048A4 (fr) | Méthodes et compositions pour le traitement de l'amyloïdose | |
| EP3638270A4 (fr) | Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie | |
| EP3886809A4 (fr) | Méthodes et compositions pour le traitement de l'arthrose | |
| EP3452015A4 (fr) | Compositions et méthodes pour le traitement de l'inflammation ou de l'infection de l'oeil | |
| EP3373922A4 (fr) | Compositions et méthodes pour le traitement de l'homocystinurie |